Sirius Therapeutics to Present Data from its Phase 1 Clinical Trial of Factor XI siRNA, a Next-Generation Long-Acting Anticoagulant for Thromboembolic Disease, at the 66th Annual ASH Meeting and Exposition

Sirius Therapeutics

SAN DIEGO & SHANGHAI-Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next-generation siRNA therapeutic in clinical development for the prevention and treatment of thromboembolic diseases, will be presented at the American Society of Hematology (ASH) 66th Annual Meeting & Exposition. The meeting will be held December 7-10, 2024 at the San Diego Convention Center and online.

“The data presented at ASH 2024 demonstrate a favorable safety and efficacy profile of SRSD107, pointing to its potential as a transformative drug with semi-annual or even annual dosing for patients requiring a chronic anticoagulant”

The data presented at ASH 2024 demonstrate a favorable safety and efficacy profile of SRSD107, pointing to its potential as a transformative drug with semi-annual or even annual dosing for patients requiring a chronic anticoagulant,” said Dr. Patrick Yue, CMO of Sirius Therapeutics.

This announcement is officially valid in the original source language. Translations are provided as a reading aid only and should be compared with the source-language text, which alone has legal validity.

Contacts

info@siriusrna.com

Official website:
www.siriusrna.com

Suscribirse al boletín informativo

Email Subscription Form

Copyright © Todas las marcas son propiedad de la respectiva empresa o de BORGES MEDIA INC. Queda prohibida la reproducción total o parcial de cualquiera de los contenidos que aquí aparecen, así como su traducción a cualquier idioma sin autorización escrita de su propietario, la mejor revista de Sacramento. Consulte nuestra  Política de Privacidad.